Aug 20, 2026 · 9 min
SK Hynix rallies as Kuaishou absorbs AI costs
SK Hynix Up, Kuaishou Plunges, Sino Biopharmaceutical Up
The episode connects corporate capital returns, AI spending pressure, healthcare optimism and Walmart’s expanding EV ambitions across markets.
- 1SK Hynix shares surged after announcing a $29 billion buyback and higher shareholder-return target.
- 2Kuaishou’s stock fell as weak guidance and rising AI development costs pressured investor expectations.
- 3Asian healthcare stocks gained after Moderna and Merck reported a breakthrough in skin cancer vaccine trials.
Don't miss
SK Hynix shares jump 11% after the company announces a $29 billion buyback and raises its shareholder-return target.
The brief
SK Hynix’s $29 billion buyback and increased shareholder-return target sent its shares up 11%, making capital allocation the episode’s clearest market signal.
Equities reporter Winnie Sue joins the discussion of Asia’s movers, including Kuaishou’s steep decline as weak guidance collided with high AI development costs.
Healthcare stocks received a lift after Moderna and Merck’s skin cancer vaccine trial breakthrough, showing how clinical news can quickly reshape sector sentiment.
The report closes with Walmart’s aggressive expansion into electric-vehicle charging, a retail strategy now reaching beyond stores and into transportation infrastructure.
What was said on this episode
10 statements · 7 positive · 1 negative · 2 neutral
SK Hynix management signals confidence in future company growth.
“management is very confident in terms of the future growth of the company”
Listen at 1:50
SK Hynix plans further cash returns for investors.
“there is further cash returns that it's planning for its investors”
Listen at 1:56
Kuaishou’s high AI development costs reduce company income.
“the high cost of developing a centered business is really weighing on the company's income”
Listen at 2:51
Moderna-Merck personalized vaccine reduces melanoma recurrence.
“a personalized vaccine co developed by Moderna and Merck to reduce the recurrence of melanoma”
Listen at 4:03
The Moderna-Merck trial is the first positive late-stage mRNA cancer-therapy trial.
“this is the first time we are seeing a positive late stage trial for any M RNA based cancer therapy”
Listen at 4:28
The vaccine can be customized to patients’ specific tumor mutations.
“they can customize the vaccines based on the patient's specific tumor mutations”
Listen at 4:39
The personalized cancer vaccine still requires regulatory approval.
“it has to be approved”
Listen at 5:08
The personalized cancer vaccine timeline extends to 2027 or later.
“we are looking at the timeline at 2027 plus”
Listen at 5:10
Walmart has become a major player in electric-vehicle charging.
“Walmart has become a major player in the burgeoning business of quickly fueling electric vehicles”
Listen at 6:11
Walmart is rapidly building its own EV charging network.
“Walmart is building its own network and quickly”
Listen at 6:49
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
KuaishouBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.